How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer

Clark, Gary M.; Wenger, Robert; Beardslee, Brian; Owens, Marilyn A.; Pounds, B S George; Oldaker, B A Teri; Vendely, Patricia; Pandian, M. R.; Harrington, Douglas S.; McGuire, William

doi:10.1002/1097-0142(19930315)71:6+<2157::aid-cncr2820711606>3.0.co;2-o

Cited by 67 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels of 3 fmol/mg protein or greater were considered positive for ER, and levels of 5 fmol/mg protein or greater were considered positive for PgR. DNA ploidy and S-phase fraction were evaluated using flow cytometry, as previously described [24-26]. S-phase fractions below 6% were considered low, those in the range 6–10% were considered intermediate, and those in excess of 10% were considered high.…”

Section: Methodsmentioning

confidence: 99%

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

et al. 2004

View full text Add to dashboard Cite

Carcinoma of the breast is a histologically heterogeneous disease. Invasive lobular carcinoma (ILC) accounts for 8-14% of all breast cancers [1,2]. Data from a recent epidemiologic study [3] indicate that for unknown causes the incidence of this type of breast cancer is increasing, especially among postmenopausal women.The morphologic features of lobular carcinoma differ from those of ductal carcinoma. ILC is characterized by small, round cells that are bland in appearance and have scant cytoplasm, which infiltrate the stroma in single file and surround benign breast tissues in a targeted manner [1,4]. Infiltration typically does not destroy anatomic structures or incite a substantial connective tissue response. By virtue of their distinctive growth pattern and biology, lobular carcinomas often fail to form distinct masses that can easily be diagnosed by palpation or mammography. This can make early diagnosis challenging [5,6] and breast conservation approaches more difficult. Lobular carcinomas may have a substantially increased propensity for multifocal and multicentric distribution and for bilaterality [5,[7][8][9][10][11]. Metastatic spread with an uncommon pattern of involvement has been reported [12,13]. CNS = central nervous system; DFS = disease-free survival; EGFR = epidermal growth factor receptor; ER = estrogen receptor; IDC = infiltrating ductal carcinoma; ILC = infiltrating lobular carcinoma; OS = overall survival; PgR = progesterone receptor. AbstractIntroduction: Invasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors.

show abstract

Section: Methodsmentioning

confidence: 99%

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

et al. 2004

View full text Add to dashboard Cite

show abstract

“…As to the interval time of post-operative monitoring, patients were divided into 2 groups: at low and at intermediate-high risk of recurrence according to whether they were N-PgR+ or N+ and/or PgR- (N+ PgR+, N+ PgR-, N- PgR-) respectively. Axillary lymph-nodes (N+/N-) [28] and progesterone (PgR+/PgR-) status [29,30] were used to divide patients into two different risk groups as they are commonly reported among the principal prognostic factors for relapse. The 126 low risk patients underwent control visits every 6 months and the remaining 142 with intermediate-high risk of recurrence every 4 months.…”

Section: Methodsmentioning

confidence: 99%

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

et al. 2006

View full text Add to dashboard Cite

Background: In breast cancer current guidelines do not recommend the routine use of serum tumour markers. Differently, we observed that CEA-TPA-CA15.3 (carcinoembryonic (CEA) tissue polypeptide (TPA) and cancer associated 115D8/DF3 (CA15.3) antigens) panel permits early detection and treatment for most relapsing patients. As high sensitivity and specificity and different cut-off values have been reported for mucin-like carcinoma associated antigen (MCA), we compared MCA with the above mentioned tumour markers and MCA-CA15.3 with the CEA-TPA-CA15.3 panel. Methods:In 289 breast cancer patients submitted to an intensive post-operative follow-up with tumour markers, we compared MCA (cut-off values, ≥ 11 and ≥ 15 U/mL) with CEA or CA15.3 or TPA for detection of relapse. In addition, we compared the MCA-CA15.3 and CEA-TPA-CA15.3 tumour marker panels. Results: Distant metastases occurred 19 times in 18 (6.7%) of the 268 patients who were disease-free at the beginning of the study. MCA sensitivity with both cut-off values was higher than that of CEA or TPA or CA15.3 (68% vs 10%, 26%, 32% and 53% vs 16%, 42%, 32% respectively). With cut-off ≥ 11 U/mL, MCA showed the lowest specificity (42%); with cut-off ≥ 15 U/mL, MCA specificity was similar to TPA (73% vs 72%) and lower than that of CEA and CA15.3 (96% and 97%

show abstract

“…Both node-negative and node-positive breast cancer patients contain identifiable subgroups with greatly different prognosis (Hedley et al, 1987;Sigurdsson et al, 1990;Ewers et al, 1991;Clark et al, 1992;Joensuu and Toikkanen, 1992). Evidence from a large number of studies indicates an association between high Sphase fraction (SPF) and a shorter disease-free survival and overall survival of patients with breast cancer (Hedley et al, 1987;Kallioniemi et al, 1988;StAl et al, 1989;Toikkanen et al, 1989;Uyterlinde et al, 1990;Ewers et al, 1991;Joensuu and Toikkanen, 1992;O'Reilly et al, 1992;Clark et al, 1993). Patients with aneuploid tumours also tend to have a worse prognosis than those with diploid tumours (Hedley et al, 1987;Kallioniemi et al, 1987;StAl et al, 1989;Toikkanen et al, 1989;Uyterlinde et al, 1990).…”

mentioning

confidence: 99%

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Hietanen

Blomqvist²,

Wasenius³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.

show abstract

How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer

Cited by 67 publications

References 5 publications

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Contact Info

Product

Resources

About